Role of smooth muscle cell p53 in pulmonary arterial hypertension.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 16 11 2018
accepted: 11 02 2019
entrez: 27 2 2019
pubmed: 27 2 2019
medline: 26 11 2019
Statut: epublish

Résumé

Pulmonary arterial hypertension (PAH) is characterized by remodeling and narrowing of the pulmonary arteries, which lead to elevation of right ventricular pressure, heart failure, and death. Proliferation of pulmonary artery smooth muscle cells (PASMCs) is thought to be central to the pathogenesis of PAH, although the underlying mechanisms are still being explored. The protein p53 is involved in cell cycle coordination, DNA repair, apoptosis, and cellular senescence, but its role in pulmonary hypertension (PH) is not fully known. We developed a mouse model of hypoxia-induced pulmonary hypertension (PH) and found significant reduction of p53 expression in the lungs. Our in vitro experiments with metabolomic analyses and the Seahorse XF extracellular flux analyzer indicated that suppression of p53 expression in PASMCs led to upregulation of glycolysis and downregulation of mitochondrial respiration, suggesting a proliferative phenotype resembling that of cancer cells. It was previously shown that systemic genetic depletion of p53 in a murine PH model led to more severe lung manifestations. Lack of information about the role of cell-specific p53 signaling promoted us to investigate it in our mouse PH model with the inducible Cre-loxP system. We generated a mouse model with SMC-specific gain or loss of p53 function by crossing Myh11-Cre/ERT2 mice with floxed Mdm4 mice or floxed Trp53 mice. After these animals were exposed to hypoxia for 4 weeks, we conducted hemodynamic and echocardiographic studies. Surprisingly, the severity of PH was similar in both groups of mice and there were no differences between the genotypes. Our findings in these mice indicate that activation or suppression of p53 signaling in SMCs has a minor role in the pathogenesis of PH and suggest that p53 signaling in other cells (endothelial cells, immune cells, or fibroblasts) may be involved in the progression of this condition.

Identifiants

pubmed: 30807606
doi: 10.1371/journal.pone.0212889
pii: PONE-D-18-32948
pmc: PMC6391010
doi:

Substances chimiques

RNA, Small Interfering 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0212889

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H944-H957
pubmed: 27591215
Nature. 2007 Mar 22;446(7134):444-8
pubmed: 17334357
Cell Metab. 2013 Oct 1;18(4):491-504
pubmed: 24093674
Nat Med. 2016 Jan;22(1):78-83
pubmed: 26657143
Cell Physiol Biochem. 2017;42(4):1603-1613
pubmed: 28738389
Circ Res. 2014 Jun 20;115(1):148-64
pubmed: 24951764
BMJ. 2018 Mar 14;360:j5492
pubmed: 29540357
Cell Metab. 2014 Dec 2;20(6):967-77
pubmed: 25456739
Am J Physiol Lung Cell Mol Physiol. 2011 May;300(5):L753-61
pubmed: 21335523
Cell Metab. 2012 Jan 4;15(1):51-64
pubmed: 22225876
Cell Rep. 2014 Jun 12;7(5):1691-1703
pubmed: 24857662
Mol Cell Biol. 2006 Jan;26(1):192-8
pubmed: 16354690
Cell. 2017 Mar 23;169(1):132-147.e16
pubmed: 28340339
Aging Cell. 2016 Oct;15(5):973-7
pubmed: 26864908
N Engl J Med. 2015 Aug 27;373(9):834-44
pubmed: 26308684
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Cell Metab. 2014 Apr 1;19(4):558-73
pubmed: 24508506
J Clin Invest. 2013 Mar;123(3):966-72
pubmed: 23454759
Nature. 1992 Jul 2;358(6381):15-6
pubmed: 1614522
N Engl J Med. 2013 Jul 25;369(4):330-40
pubmed: 23883378
J Mol Cell Cardiol. 2015 Aug;85:183-98
pubmed: 26055447
Circulation. 2010 May 11;121(18):2045-66
pubmed: 20458021
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066

Auteurs

Takayuki Wakasugi (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Ippei Shimizu (I)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Yohko Yoshida (Y)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Yuka Hayashi (Y)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Ryutaro Ikegami (R)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Masayoshi Suda (M)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Goro Katsuumi (G)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Masaaki Nakao (M)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Makoto Hoyano (M)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Takeshi Kashimura (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Kazufumi Nakamura (K)

Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Hiroshi Ito (H)

Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Takashi Nojiri (T)

Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita-City, Osaka, Japan.

Tomoyoshi Soga (T)

Institute for Advanced Biosciences, Keio University, Yamagata, Japan.

Tohru Minamino (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH